Land: Israël
Taal: Engels
Bron: Ministry of Health
VALPROIC ACID AS SODIUM
MEGAPHARM LTD
N03AG01
SOLUTION FOR INJECTION / INFUSION
VALPROIC ACID AS SODIUM 300 MG / 3 ML
I.V
Required
DESITIN ARZNEIMITTEL GMBH, GERMANY
VALPROIC ACID
VALPROIC ACID
Treatment of generalized seizures in the form of absence, myoclonic and tonic-clonic seizures and partial and secondary generalized seizures.
2015-02-28
1. NAME OF THE MEDICINAL PRODUCT ORFIRIL INJECTION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION VALPROIC ACID (AS SODIUM)100 mg/ ml One ampoule with 3 ml solution for injection contains 300 mg of sodium valproate (equivalent to 260.28 mg of valproic acid). One ampoule with 10 ml solution for injection contains 1,000 mg of sodium valproate (equivalent to 867.6 mg of valproic acid). Excipient(s) with known effect: 1 ampoule with 3 ml solution for injection contains 1.81 mmol (41.6 mg) sodium. 1 ampoule with 10 ml solution for injection contains 6.0 mmol (138.8 mg) sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of: - Generalized seizures in the form of absences, myoclonic and tonic-clonic seizures - Partial and secondary generalized seizures. Combination treatment of other forms of seizures. ORFIRIL INJECTION solution is used if oral sodium valproate therapy cannot be given. _Note: _ In infants, sodium valproate is the first-line drug only in exceptional cases; it should be used only with great caution and after careful consideration of the risk-benefit ration and, if possible, as monotherapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ORFIRIL INJECTION is intended exclusively for intravenous administration. The dosage should be determined according to age and weight and monitored individually by the physician on the basis of concentration determinations. Close monitoring of plasma levels and - if necessary - dosage adjustments have to be performed during the change-over to a parenteral therapy, during the parenteral therapy and during the switch back to oral therapy, in particular in such patients receiving higher doses of valproate or in patients receiving medicinal products potentially influencing the metabolism of valproate. Therapeutic efficacy is usually reached at plasma levels between 50 and 100 mg/L (340-700 mol/L). The mean daily dosages during maintenance treatment are as follows: Child Lees het volledige document